Genprex said its collaborators will present preclinical data on Reqorsa (quaratusugene ozeplasmid) for lung cancer at the 2026 AACR Annual Meeting on April 19, 2026. One poster reports that low TROP2 and high PTEN expression were identified as potential biomarkers associated with primary resistance to TUSC2 gene therapy in non-small cell lung cancer models. Another poster describes studies in ALK-positive non-small cell lung cancer showing 79% tumor shrinkage with Reqorsa alone or with alectinib in an alectinib-sensitive mouse model, compared with 60% tumor shrinkage with alectinib alone. A third poster reports that restoring TUSC2 function increased natural killer cell cytotoxicity and led to complete tumor regression in 67% of Tusc2 knockout mice and 33% of wild-type mice in a syngeneic tumor model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603180700PR_NEWS_USPR_____DA12135) on March 18, 2026, and is solely responsible for the information contained therein.